SEEHRA JASBIR has a total of 14 patent applications. Its first patent ever was published in 2008. It filed its patents most often in United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are ALPINE IMMUNE SCIENCES INC, ESPERANCE PHARMACEUTICALS INC and TYKOCINSKI MARK L.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 14 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Measurement | |
#5 | Organic fine chemistry | |
#6 | Machines |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Enzymes | |
#6 | Analysing materials | |
#7 | Measuring microorganism processes | |
#8 | Sugars | |
#9 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Seehra Jasbir | 14 |
#2 | Kumar Ravindra | 9 |
#3 | Knopf John | 5 |
#4 | Pearsall Robert Scott | 3 |
#5 | Lachey Jennifer | 3 |
#6 | Koncarevic Alan | 2 |
#7 | Martinez-Hackert Erik | 1 |
#8 | Grinberg Asya | 1 |
#9 | Pearsall Robert S | 1 |
#10 | Vogan Erik | 1 |
Publication | Filing date | Title |
---|---|---|
US2011038831A1 | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators | |
US2009304691A1 | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |